References
1. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and
Projection of Optimized Dosing Design of Hydroxychloroquine for the
Treatment of Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2). Clin Infect Dis . Published online 9 March 2020.
doi:10.1093/cid/ciaa237
2. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in
patients with COVID-19: results of a randomized clinical trial.medRxiv . Published online 10 April 2020:2020.03.22.20040758.
doi:10.1101/2020.03.22.20040758
3. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and
azithromycin as a treatment of COVID-19: results of an open-label
non-randomized clinical trial. Int J Antimicrob Agents . Published
online 20 March 2020:105949. doi:10.1016/j.ijantimicag.2020.105949
4. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for
Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med .
2021;384(6):497-511. doi:10.1056/NEJMoa2023184
5. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of
Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl
J Med . 2020;383(21):2030-2040. doi:10.1056/NEJMoa2022926
6. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine
and chloroquine: implications for rheumatology. Nat Rev
Rheumatol . doi:10.1038/s41584-020-0372-x
7. FICHA TECNICA DOLQUINE 200 mg COMPRIMIDOS RECUBIERTOS. Summary of
Product Characteristics. Accessed July 21, 2021.
https://cima.aemps.es/cima/dochtml/ft/74904/FT_74904.html
8. Velasco-González V, Fernández-Araque A, Sainz-Gil M, Jimeno N, Martín
LH, Verde Z. Hydroxychloroquine and Potential Drug Interactions in Older
Adults. Arch Bronconeumol . 2020;56(10):679-681.
doi:10.1016/j.arbres.2020.06.001
9. Aguirre C, García M. Evaluación de la causalidad en las
comunicaciones de reacciones adversas a medicamentos. Algoritmo del
Sistema Español de Farmacovigilancia. Med Clin (Barc) .
2016;147(10):461-464. doi:10.1016/j.medcli.2016.06.012
10. Brown EG, Wood L WS. The medical dictionary for regulatory
activities (MedDRA). Drug Saf . 1999;20:109-117.
11. Faillie J-L. Case–non-case studies: Principle, methods, bias and
interpretation. Therapies . 2019;74(2):225-232.
doi:10.1016/j.therap.2019.01.006
12. ICH. Introductory Guide for Standardised MedDRA Queries (SMQs)
Version 24.0 .; 2021.
13. Norén GN, Sundberg R, Bate A, Edwards IR. A statistical methodology
for drug-drug interaction surveillance. Stat Med .
2008;27(16):3057-3070. doi:10.1002/sim.3247
14. Agencia española de medicamentos y productos sanitarios (AEMPS). La
AEMPS informa de la distribución controlada de todo el stock de
hidroxicloroquina/cloroquina. Published online 2020.
15. Alvarez A, Cabia L, Trigo C, Bandrés AC, Bestué M. Prescription
profile in patients with SARS-CoV-2 infection hospitalised in Aragon,
Spain. Eur J Hosp Pharm . 2020;669:ejhpharm-2020-002476.
doi:10.1136/ejhpharm-2020-002476
16. Bull-Otterson L, Gray EB, Budnitz DS, et al. Hydroxychloroquine and
Chloroquine Prescribing Patterns by Provider Specialty Following Initial
Reports of Potential Benefit for COVID-19 Treatment — United States,
January–June 2020. MMWR Morb Mortal Wkly Rep .
2020;69(35):1210-1215. doi:10.15585/mmwr.mm6935a4
17. Shehab N, Lovegrove M, Budnitz DS. US Hydroxychloroquine,
Chloroquine, and Azithromycin Outpatient Prescription Trends, October
2019 Through March 2020. JAMA Intern Med . 2020;180(10):1384.
doi:10.1001/jamainternmed.2020.2594
18. Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse
prognosis in COVID-19: A systematic review and meta-analysis. Eur
J Clin Invest . 2020;50(10):e13362. doi:10.1111/eci.13362
19. Fiehn C, Ness T, Weseloh C, et al. Safety management in treatment
with antimalarials in rheumatology. Interdisciplinary recommendations on
the basis of a systematic literature review. Z Rheumatol .
2021;80(S1):1-9. doi:10.1007/s00393-020-00785-4
20. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and
pharmacological properties of hydroxychloroquine and chloroquine in
treatment of systemic lupus erythematosus, rheumatoid arthritis and
related diseases. Inflammopharmacology . 2015;23(5):231-269.
doi:10.1007/S10787-015-0239-Y
21. AEMPS. Información Acerca Del Uso de Hidroxicloroquina Para El
Tratamiento de COVID-19 .; 2020.
22. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly
pathogenic human coronavirus infections. Liver Int .
2020;40(5):998-1004. doi:10.1111/LIV.14435
23. Falcão F, Viegas E, Carmo I, et al. A prospective, observational
study to evaluate adverse drug reactions in patients with COVID-19
treated with remdesivir or hydroxychloroquine: A preliminary report.Eur J Hosp Pharm . Published online 15 January
2021:ejhpharm-2020-002613. doi:10.1136/ejhpharm-2020-002613
24. Dauner DG, Dauner KN. Summary of adverse drug events for
hydroxychloroquine, azithromycin, and chloroquine during the COVID-19
pandemic. J Am Pharm Assoc . 2021;61(3):293-298.
doi:10.1016/j.japh.2021.01.007
25. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with
or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J
Med . 2020;383(21):2041-2052. doi:10.1056/nejmoa2019014
26. Doyno C, Sobieraj DM, Baker WL. Toxicity of chloroquine and
hydroxychloroquine following therapeutic use or overdose. Clin
Toxicol . Published online 2020. doi:10.1080/15563650.2020.1817479
27. Lane JCE, Weaver J, Kostka K, et al. Risk of hydroxychloroquine
alone and in combination with azithromycin in the treatment of
rheumatoid arthritis: a multinational, retrospective study. Lancet
Rheumatol . 2020;2(11):e698-e711. doi:10.1016/S2665-9913(20)30276-9
28. FICHA TECNICA DUPLAXIL 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
EFG. Summary of Product Characteristics. Accessed July 26, 2021.
https://cima.aemps.es/cima/dochtml/ft/84048/FT_84048.html
29. Sharma AN, Mesinkovska NA, Paravar T, Jolla L. Characterizing the
adverse dermatologic effects of hydroxychloroquine: A systematic review.
doi:10.1016/j.jaad.2020.04.024
30. Hamm BS, Rosenthal LJ. Psychiatric Aspects of Chloroquine and
Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019:
Psychopharmacological Interactions and Neuropsychiatric Sequelae.
31. Garcia P, Revet A, Yrondi A, Rousseau V, Degboe Y, Montastruc F.
Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease
2019 (COVID-19): A VigiBase Study. Drug Saf .
2020;43(12):1315-1322. doi:10.1007/s40264-020-01013-3
32. Medicines Agency E. New product information wording-Extracts from
PRAC recommendations on signals.
33. Hazell L, Shakir SAW. Under-Reporting of Adverse Drug Reactions A
Systematic Review. Drug Saf . 2006;29(5):385-396.
34. Maciá-Martínez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B,
Wisniewski AFZ. An Empirical Approach to Explore the Relationship
Between Measures of Disproportionate Reporting and Relative Risks from
Analytical Studies. Drug Saf . 2016;39(1):29-43.
doi:10.1007/s40264-015-0351-3
35. Farcaş A, Măhălean A, Bulik NB, Leucuta D, Mogoșan C. New safety
signals assessed by the Pharmacovigilance Risk Assessment Committee at
EU level in 2014–2017.https://doi.org/101080/1751243320181526676 .
2018;11(10):1045-1051. doi:10.1080/17512433.2018.1526676
36. Drugsite Trust. Hydroxychloroquine Drug Interactions - Drugs.com.
Accessed March 26, 2020.
https://www.drugs.com/drug-interactions/hydroxychloroquine.html
37. Wisniewski AFZ, Bate A, Bousquet C, et al. Good Signal Detection
Practices: Evidence from IMI PROTECT. Drug Saf . 2016;39(6):469.
doi:10.1007/S40264-016-0405-1
Table 1. Characteristics of the reported cases